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Abstract Arabidopsis Toc33 (atToc33) is a GTP-binding pro-
tein of the chloroplast outer envelope membrane. We studied its
nucleotide-binding properties in vitro, and found that it binds
GTP, GDP and XTP, with similar e⁄ciencies, but not ATP.
We further demonstrated that atToc33 has intrinsic GTPase
activity. Mutations within the putative G4 motif of the atToc33
nucleotide-binding domain (D217N, D219N and E220Q) had no
e¡ect on nucleotide speci¢city or GTPase activity. Similarly, a
mutation in the newly assigned G5 motif (E208Q) did not a¡ect
nucleotide speci¢city or GTPase activity. Furthermore, the
D217N and D219N mutations did not a¡ect atToc33 function-
ality in vivo. The data demonstrate that atToc33 belongs to a
novel class of GTPases with unusual nucleotide-binding proper-
ties.
4 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The majority of proteins within chloroplasts are nucleus
encoded [1]. The mechanism for translocating nucleus-en-
coded proteins from the cytosol into the interior of chloro-
plasts involves translocons in the outer and inner envelope
membranes called Toc and Tic, respectively [2,3]. Precursor
proteins (preproteins) targeted to chloroplasts carry an N-ter-
minal transit peptide that is recognised by the Toc complex
prior to envelope translocation. The recognition of prepro-
teins by the import apparatus has not been precisely de¢ned,
but it involves GTP-binding receptors in the outer envelope
membrane called Toc34 and Toc159 [4^7]. Accordingly, GTP
has been shown to have a positive e¡ect on the early stages of
chloroplast protein import in vitro [4,8]. Following recogni-
tion, preproteins are transferred to Toc75, a major constituent
of the outer envelope translocation channel, and then trans-
located simultaneously across both envelope membranes. The
transit peptide is cleaved upon arrival in the stroma, and the
mature protein is then folded into its ¢nal conformation or
targeted to one of several internal compartments [2,3].
There are currently two models for preprotein recognition
by the Toc receptors. In the ¢rst, Toc159 and Toc34 remain
stably associated with the outer envelope membrane and in-
teract with incident preproteins directly, much like the mito-
chondrial protein import receptors, Tom20 and Tom22 [9]. In
support of this model, preproteins can be cross-linked to
Toc159 and Toc34 very early during import into isolated
chloroplasts [10], and a direct and speci¢c interaction between
preproteins and Toc34 has been observed in vitro [11]. In the
second model, soluble Toc159 binds to preproteins in the
cytosol, and then mediates their targeting to the chloroplast
surface by docking at membrane-bound Toc34 [12]. In sup-
port of this model, an abundant cytosolic form of Toc159 has
been observed [12], and the crystal structure of Toc34 suggests
that heterodimerisation between Toc34 and Toc159 may be
possible [13]. This model is reminiscent of signal recognition
particle (SRP)-dependent protein targeting, in which the GTP-
binding protein, SRP54, initiates preprotein translocation by
docking at receptors that are themselves GTP-binding pro-
teins [14].
Attempts have been made to elucidate the roles of the Toc
receptors by manipulating their activities using guanine nucle-
otide analogues [4,8]. However, it was not possible to attribute
the e¡ects of these manipulations to a single translocon com-
ponent, since there are at least two di¡erent GTP-binding Toc
proteins. In fact, at least ¢ve di¡erent GTP-binding Toc com-
ponents have been identi¢ed in Arabidopsis [15,16] : two Toc34
homologues, atToc33 and atToc34, and at least three Toc159
homologues, atToc159, atToc132 and atToc120. To manipu-
late one of these Toc proteins independently of the others, one
would ¢rst need to change its nucleotide speci¢city. Since
steady-state concentrations of XTP and XDP are relatively
low in cells [17], a change of speci¢city from guanine nucleo-
tides to xanthine nucleotides would be particularly desirable.
GTP-binding proteins are characterised by the presence of
several conserved sequence motifs (G1 to G4) within their
nucleotide-binding domains [18]. The protein import recep-
tors, Toc159 and Toc34, also appear to have these conserved
sequence motifs [4,7], and mutations within the putative G1
(GGVGKSCRGVGNR) and G4 (NKNDCNKKL) motifs
of pea Toc34 (psToc34) have been shown to impair GTP
binding [19]. Several studies using a variety of di¡erent
GTP-binding proteins have demonstrated that nucleotide
speci¢city can be changed from guanine nucleotides to xan-
thine nucleotides by a single Asp-to-Asn mutation within the
G4 motif (NKXDCNKXN) [20^23]. To better understand
the function of Arabidopsis atToc33 (the presumed orthologue
of psToc34 [15]), we characterised its nucleotide-binding and
-hydrolysing properties in vitro, and attempted to change its
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nucleotide speci¢city by mutating the putative G4 motif
[4,7,19] and a recently assigned G5 motif [13].
2. Materials and methods
2.1. Bacterial overexpression and site-directed mutagenesis
Plasmid pRSET: :atToc33 was created by ligating a polymerase
chain reaction (PCR) product corresponding to amino acid residues
1^262 of Arabidopsis thaliana Toc33 (atToc33) [15] into pRSET B
(Invitrogen). The PCR product was ampli¢ed from atToc33 cDNA
[15] using forward (5P-GGAGCCATGGGGTCTCTCGTTCGTGAA-
TG-3P) and reverse primers (5P-CTTTATCATCAGAGTAAGCTT-
CATCTACCATC-3P) that introduced NcoI and HindIII restriction
sites at the 5P and 3P ends, respectively. The NcoI site was at the start
codon, creating an in-frame fusion with six His codons located up-
stream of the pRSET B polylinker. The pRSET: :atToc33 clone was
con¢rmed by sequencing and introduced into Escherichia coli strain
BL21-DE3 (Novagen). Soluble atToc33 protein lacking the transmem-
brane domain (atToc33vTM) was overexpressed by inducing mid-ex-
ponential phase cultures with 1 mM IPTG (isopropyl L-D-thiogalacto-
side), and puri¢ed under native conditions using Ni-NTA resin
(Qiagen). atToc33vTM was eluted using 250 mM imidazole and dia-
lysed against 10% (v/v) glycerol, 1 mM dithiothreitol, 50 mM Tris^
HCl, pH 8.0, at 4‡C overnight. The protein was quanti¢ed using
Bradford reagent (Bio-Rad).
Point mutations were generated by overlap extension PCR [24] us-
ing pRSET: :atToc33 as template. Primary ampli¢cation reactions
were carried out using the following primer pairs: A1 (5P-TA-
GAGTCGATGAGCTAGATAAGC-3P) with A2 (5P-GTTCTTGCT-
GCATCTTCCGCTGTTC-3P) ; and B1 (the mutagenic primer) with
B2 (5P-CTTTATCATCAGAGTAAGCTTCATCTACCATC-3P). The
B1 primers used were: for atToc33D217N, 5P-GGAAGATGCAGCAA-
GAACAACAAGGACGAAAAGG-3P ; for atToc33D219N, 5P-GGAA-
GATGCAGCAAGAACGATAAGAACGAAAAGG-3P ; for atToc3-
3D217N=D219N, 5P-GGAAGATGCAGCAAGAACAACAAGAACGA
AAAGG-3P ; for atToc33D219N=E220Q, 5P-GGAAGATGCAGCAAGA
ACGATAAGAACCAGAAGG-3P ; and for atToc33E208Q, 5P-GCAC
AGAACAGCGGAAGATGC-3P. Following gel isolation, the pri-
mary ampli¢cation products were used as template for the overlap
extension PCR reactions using primers A1 and B2. The overlap ex-
tension ampli¢cation products were cloned into pRSET: :atToc33 as
BstXI^HindIII fragments, replacing the wild-type sequence, and the
presence of each mutation was con¢rmed by sequencing.
Plasmid pET14b encoding wild-type, hexahistidinyl-tagged Rab5
[21] was introduced into E. coli strain BL21-DE3 for the expression
of Rab5 protein. Expression and puri¢cation of Rab5 was carried out
as described for atToc33vTM.
2.2. Nucleotide-binding assays
Nucleotide analogues carrying the N-methyl-3P-O-anthraniloyl
(mant) £uorophore were used [25]. Binding bu¡er contained 10%
(v/v) glycerol, 5 mM MgCl2, 2 mM dithiothreitol and 50 mM Tris^
HCl, pH 8.0. Fluorescence measurements were recorded using a £uo-
rescence spectrophotometer (Varian Eclipse). Excitation was at 350
nm (10 nm slit), and emission was recorded between 400 nm and
600 nm. Fluorescence spectra were recorded 0 min (T0) and 7 min
(T7) after adding 3 WM protein to 0.1 WM mant-ATP, 0.1 WM mant-
GTP, 0.1 WM mant-GDP or 0.1 WM mant-XTP (Jena Bioscience).
Spectra were adjusted so that £uorescence values at 600 nm were
equal to zero, and then normalised so that T0 £uorescence maxima
were equal to one. Di¡erence spectra (400^540 nm) were obtained by
subtracting the T0 values from the T7 values.
2.3. GTP-hydrolysis assays
atToc33vTM protein (0.1 Wg) was incubated with 1 WCi [K-32P]GTP
(3000 Ci/mmol; NEN) at 37‡C in 10 Wl bu¡er (50 mM NaCl, 2 mM
dithiothreitol, 1 mM MgCl2, 20 mM Tricine^KOH, pH 7.6); for
competition experiments, unlabelled nucleotides were added prior to
the addition of atToc33vTM protein at the indicated concentrations.
Aliquots (1 Wl) were removed after 5, 15, 30 and 60 min, spotted onto
PEI-cellulose thin layer chromatography (TLC) strips (Macherery-Na-
gel), and separated using 600 mM Na2H2PO4, pH 3.4. Dried strips
were exposed to X-ray ¢lm, and the bands were quanti¢ed using
ImageQuant software (Molecular Dynamics).
2.4. Genetic complementation studies
A 6.5 kb XbaI fragment carrying the complete atToc33 gene [15]
was ligated into pUC19 to create pUC: :atToc33g. Codon changes
were generated by overlap extension PCR mutagenesis, using
pUC: :atToc33g as template. The primary ampli¢cation reactions
were carried out using the following primer pairs: A1 with A2; and
B1 (for atToc33D217N and atToc33D219N) with C2 (5P-CCTCTTCTT
CAGAGCCTCTTAAA-3P). The overlap extension ampli¢cation reac-
tions were carried out with primers A1 and C2. The products were
cloned in pGEM-T Easy (Promega) and veri¢ed by sequencing. Mu-
tant BstXI^EcoRV fragments from the pGEM-T clones were used to
replace the corresponding wild-type sequence in pUC: :atToc33g, cre-
ating pUC: :atToc33gD217N and pUC: :atToc33gD219N, and the muta-
tions were con¢rmed by sequencing. Finally, 6.5 kb XbaI genomic
fragments from pUC: :atToc33gD217N and pUC: :atToc33gD219N were
introduced into plant transformation vector, pPZP221 [26], to create
pPZP: :atToc33gD217N and pPZP: :atToc33gD219N. These two con-
structs were used to transform plastid protein import 1 (ppi1) mutant
Arabidopsis plants by £oral dipping [15,27].
Transgenic plants were selected by plating the T1 generation on
Murashige and Skoog medium (Sigma) containing 0.5% (w/v) sucrose,
110 Wg/ml (w/v) gentamicin sulphate and 200 Wg/ml (w/v) cefotaxime
sodium; in vitro plant growth procedures were as described previously
[28]. Gentamicin-resistant seedlings were transferred to soil after 14
day and allowed to set seed. To con¢rm the presence of the atToc33
transgenes, DNA isolated from T2 seedlings [29] was analysed by
PCR using the transgene-speci¢c primers, C1 (5P-GGTCTCTCGTT-
CGTGAATGG-3P) and C2. The presence of the mutations was con-
¢rmed by sequencing the PCR products. Homozygosity at the ppi1
T-DNA insertion was con¢rmed by plating T2 seed on medium con-
taining 50 Wg/ml (w/v) kanamycin monosulphate [15].
Genetic complementation of the ppi1 mutation was quanti¢ed by
measuring the chlorophyll content of T2 plants. Cotyledons from 14-
to 16-day-old wild-type, ppi1, ppi1/atToc33gD217N and ppi1/atToc-
33gD219N plants grown in vitro were incubated in DMF (N,NP-di-
methylformamide) in the dark at 4‡C overnight. Chlorophyll was
determined by measuring absorbance at 646.8 and 663.8 nm and
calculated as described previously [30]. Expression of atToc33 in these
T2 lines was con¢rmed by immunoblotting using standard procedures
and an atToc33-speci¢c polyclonal antibody raised against the C-ter-
minal peptide, CQGAIRNDIKTSGKPL (Eurogentec); an antibody
raised against pea Tic110 was used as a loading control. The second-
ary antibody was an anti-rabbit IgG alkaline phosphatase conjugate
(Sigma), and the detection reagent was BCIP/NBT alkaline phospha-
tase substrate (Sigma).
3. Results and discussion
3.1. Nucleotide-binding properties of wild-type atToc33vTM
Hexahistidinyl-tagged atToc33 lacking the C-terminal
transmembrane domain (atToc33vTM) was overexpressed in
E. coli and puri¢ed by a⁄nity chromatography. The puri¢ed
protein (expected size V33 kDa) was analysed by sodium
dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) and estimated to be s 90% pure (Fig. 1B, lane 2).
To investigate the nucleotide-binding properties of the at-
Toc33vTM protein, we used an N-methyl-3P-O-anthraniloyl
(mant)-nucleotide-binding assay. The mant moiety is a £uoro-
phore that responds with di¡erent intensities and wavelengths
of £uorescence depending on the hydrophobicity of its sur-
roundings [25]. Free and bound forms of mant-nucleotides can
therefore be distinguished using a £uorescence spectropho-
tometer, enabling the study of protein^nucleotide interactions
in vitro. Excitation at 350 nm gives rise to a £uorescence
emission peak at V450 nm with unbound mant-nucleotides,
and a more intense peak atV430 nm with bound nucleotides.
When atToc33vTM protein was added to mant-GTP or mant-
GDP, a robust increase in £uorescence and a blue-shift in the
emission maximum was observed after 7 min, indicating that a
strong protein^nucleotide interaction had occurred in each
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case; these data are expressed as di¡erence spectra in Fig. 2A.
To assess the speci¢city of this interaction, we tested the abil-
ity of atToc33vTM to bind mant-ATP. As expected, no evi-
dence for an atToc33^ATP interaction was observed (Fig.
2A). However, when we conducted a similar assay using
mant-XTP, a strong atToc33^XTP interaction was clearly
seen (Fig. 2A).
It is clear from the data that wild-type atToc33 protein
binds GTP, GDP and XTP with similar e⁄ciencies, and
that the observed atToc33^GTP/GDP/XTP interactions are
speci¢c since no evidence for an atToc33^ATP interaction
was observed. The ¢nding that atToc33 binds XTP as e⁄-
ciently as it binds GTP/GDP is surprising, since most other
GTP-binding proteins tested have been found to bind GTP
several orders of magnitude more e⁄ciently than XTP [20^
23]. To con¢rm that this result was not an artefact of our
experimental procedure, we analysed a canonical GTP-bind-
ing protein, human Rab5, using exactly the same protocol.
Increased £uorescence was observed in the Rab5^GTP assay,
but not in the Rab5^XTP assay (data not shown). Since Rab5
was previously shown to bind GTP but not XTP, these results
con¢rm the validity of the experimental procedure employed
here.
The strong sequence similarity between atToc33 and
psToc34 (V60% amino acid sequence identity) suggests that
the proteins may behave similarly with respect to nucleotide
binding. Indeed, several previous studies have shown that
psToc34 does not bind ATP [4,7,11]. The inability of atToc33
(or psToc34) to bind ATP is signi¢cant with regard to its role
in chloroplast protein import. The translocation of prepro-
teins across the outer envelope membrane requires low con-
centrations of ATP (6 100 WM) [8,28], but the site of ATP
consumption remains to be determined. Since atToc33 (or
psToc34) does not bind ATP in vitro, it is unlikely that it is
responsible for this ATP requirement.
3.2. Nucleotide-binding properties of atToc33vTM G4 mutants
In an attempt to change atToc33 nucleotide speci¢city (and
make the protein more discriminatory in favour of xanthine
nucleotides), selected residues within the putative G4 motif of
its nucleotide-binding domain were mutated. In canonical
GTP-binding proteins, the carboxyl side chain of the G4
Asp makes hydrogen bonds with NH1 and the exocyclic 2-
amino group of the guanine base. Previous studies using sev-
eral di¡erent GTP-binding proteins demonstrated that muta-
tion of the G4 Asp to Asn results in a change of speci¢city
from guanine nucleotides to xanthine nucleotides [20^23]. In
these G4 mutants, the amide side chain of the new Asn resi-
due is predicted to make hydrogen bonds with NH1 and the
2-carbonyl group of the xanthine base. Because the putative
G4 motif originally identi¢ed in psToc34 (residues 216^219)
[4,7,19] is not well conserved in other Toc34-related proteins
(Fig. 1A), three di¡erent residues that may play a role in
determining atToc33 nucleotide speci¢city were mutated: (1)
Asp 217, since it corresponds exactly to Asp 219 of the puta-
tive psToc34 G4 motif; (2) Asp 219, since the sequence
NDKD matches the G4 consensus (NKXD) more closely;
and (3) Glu 220, since it is conserved in all ¢ve Toc34-related
sequences. An analysis of V70 di¡erent GTP-binding pro-
teins demonstrated that signi¢cant deviations from the
NKXD consensus are possible [18] ; for example, the G4
motifs of Saccharomyces cerevisiae RHO2 and CDC42 are
LKKD and TQID, respectively.
Four putative atToc33 G4 mutants (D217N, D219N,
D217N/D219N and D219N/E220Q; Fig. 1A) were generated
by overlap extension PCR and cloned into the pRSET expres-
sion vector. Hexahistidinyl-tagged mutant atToc33vTM pro-
teins were overexpressed in E. coli and puri¢ed by a⁄nity
chromatography. All of the proteins were estimated to be
s 90% pure by SDS^PAGE (Fig. 1B, lanes 3^6). The nucleo-
tide-binding properties of each mutant protein were deter-
mined as described for the wild-type protein, and the data
are presented as di¡erence spectra (Fig. 2B^E). It is clear
from the data that all of the mutants have essentially the
same nucleotide-binding properties as wild-type atToc33, and
that none of the selected residues is important for determining
atToc33 nucleotide speci¢city.
Evidence was recently presented that a psToc34 D219N
mutation (the equivalent of the atToc33 D217N mutation)
does have a slight e¡ect on nucleotide speci¢city [31]. As
described above, these results are not supported by our data
(Fig. 2A,B). However, our results are fully consistent with
conclusions drawn from the crystal structure of psToc34
[13], which indicated that the Asp 219 side chain is totally
exposed to the solvent [13]. Instead, the carboxyl side chain
Fig. 1. Sequence alignment and SDS^PAGE analysis of recombinant
proteins. A: The putative G4 regions of Toc34-related proteins
from Arabidopsis (at), pea (ps) and maize (zm) are shown aligned.
Residues conserved in all sequences are shaded, and the proposed
G4 motif of psToc34 is underlined. The di¡erent mutations intro-
duced into atToc33 (D217N, D219N, E220Q and E208Q) are shown
above the alignment. For comparison, the G4 regions of human
(hs) Rab5 and E. coli (ec) EF-Tu are also shown. B: Recombinant
atToc33vTM proteins (WT, D219N/E220Q, D217N/D219N,
D219N, D217N and E208Q) were resolved by SDS^PAGE and
stained with Coomassie. Each lane holds V1 Wg protein. Molecular
weight standards (MW) are indicated in kDa.
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of Glu 210 was predicted to make one strong and one weak
hydrogen bond with NH1 and the 2-amino group of guanine,
respectively, and this residue was therefore assigned to a new
G5 motif [13]. We assessed the role of the corresponding
atToc33 residue (Glu 208; Fig. 1A) in determining nucleotide
speci¢city, but found that puri¢ed atToc33vTME208Q (Fig. 1B,
lane 7) bound GTP and XTP with similar e⁄ciencies (Fig.
2F), just like the wild-type protein (Fig. 2A). Because wild-
type atToc33vTM is able to bind both GTP and XTP, and
because atToc33vTME208Q does not show any preference for
XTP over GTP, we conclude that only the NH1 hydrogen
bond plays a signi¢cant role in nucleotide binding. Interest-
ingly, the vF values obtained for atToc33vTME208Q (GTP:
0.59T 0.05, XTP: 0.54 T 0.11; n=5) were signi¢cantly lower
than those obtained for the wild type (GTP: 1.19T 0.10,
XTP: 1.09 T 0.09; n=3). This most likely indicates weaker
nucleotide binding by atToc33vTME208Q caused by a reduc-
tion in the strength of the NH1 hydrogen bond, and is con-
sistent with a role for Glu 208 in nucleotide binding.
3.3. Wild-type atToc33vTM and the G4 mutants have intrinsic
GTPase activity
The ability of atToc33 to hydrolyse GTP has not been
studied in any detail, and there is some disagreement in the
literature concerning the ability of psToc34 to hydrolyse GTP
[7,11,13]. We therefore conducted a GTP-hydrolysis assay us-
ing wild-type atToc33vTM protein. The result, shown in Fig.
3A (left panel), clearly demonstrates that atToc33 has intrinsic
GTPase activity. To con¢rm that the GTPase activity was
attributable to atToc33 and not some contaminating E. coli
protein, we conducted an identical GTP-hydrolysis assay us-
ing a control protein that does not bind GTP (atTic22-IV)
and which was puri¢ed using a similar procedure; as expected,
no GTP hydrolysis was observed (data not shown). The fact
that puri¢ed atToc33 protein is able to hydrolyse GTP dem-
onstrates that a separate GTPase-activating protein (GAP) is
not absolutely required, and is consistent with the hypothesis
that Toc34-related proteins form dimers in which each partner
acts as the other partner’s GAP [13].
There are some reports in the literature of G4 Asp-to-Asn
mutations that do not result in a change of nucleotide speci-
¢city [32,33]. In the case of methylation-dependent restriction
endonuclease subunit, McrB, the G4 Asp-to-Asn mutation
resulted in dramatically reduced GTPase activity [33]. To de-
termine if the atToc33 G4 and G5 mutations a¡ect GTPase
activity, we conducted GTP-hydrolysis assays using each mu-
Fig. 2. Nucleotide-binding assays. Binding assays using wild-type (A) and mutant (B^F) recombinant atToc33vTM proteins, and either mant-
GTP, mant-GDP (wild type only), mant-XTP or mant-ATP, were conducted. Fluorescence spectra were recorded 0 min (T0) and 7 min (T7)
after the initiation of each binding assay, normalised, and then used to derive £uorescence di¡erence (vF) spectra by subtracting the T0 values
from the T7 values. The presented data are representative of at least three independent experiments.
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tant atToc33vTM protein. All ¢ve atToc33 mutants were
found to have similar GTPase activities to that of the wild-
type protein, but only the data obtained using atToc33-
vTMD217N, atToc33vTMD219N=E220Q and atToc33vTME208Q
are shown (Fig. 3A). Quanti¢cation of the data revealed no
signi¢cant di¡erences in reaction kinetics between the di¡erent
GTP-hydrolysis assays (Fig. 3B). The observation that the
D217N mutation does not a¡ect GTPase activity is inconsis-
tent with a previous study on an equivalent psToc34 mutant
(D219N) [31], but is fully consistent with the nucleotide-bind-
ing data presented earlier (Fig. 2) and with the crystal struc-
ture of psToc34 [13]. Because the e¡ect of E208Q on nucleo-
tide binding (Fig. 2) does not signi¢cantly in£uence GTPase
activity, we can conclude that the hydrolysis reaction rather
than nucleotide binding is rate limiting for atToc33 GTPase
activity.
To corroborate our ¢ndings on atToc33 nucleotide binding
and speci¢city, we conducted GTP-hydrolysis assays in the
presence of di¡erent concentrations of cold competitor nu-
cleotides (Fig. 3C,D). We found that GTP and XTP were
equally e¡ective as competitors in assays using wild-type at-
Toc33vTM. This is consistent with our earlier observation
that wild-type atToc33vTM binds mant-GTP and mant-XTP
with similar e⁄ciencies (Fig. 2A). Furthermore, we observed
that XTP was no more e¡ective as a competitor in GTP-hy-
drolysis assays using the di¡erent G4 and G5 mutants than in
those using wild-type atToc33vTM (Fig. 3C,D). This con¢rms
our previous conclusion that none of the mutations has a
signi¢cant e¡ect on nucleotide speci¢city in vitro. In each
competition experiment, the degree of inhibition of GTPase
activity observed was similar to that reported previously for
psToc34 [31].
3.4. Full-length atToc33 G4 mutants are functional in vivo
Because all of the assays on the atToc33 mutants described
so far were conducted in vitro using C-terminally truncated
proteins, we tested the activity of two full-length mutant pro-
teins in vivo. To do this we used a transgenic complementa-
tion assay based on the Arabidopsis atToc33 knockout mu-
tant, ppi1 [15]. The D217N and D219N mutations were
introduced into a genomic clone of the atToc33 gene without
altering any of the introns or the 5P and 3P regulatory regions.
These constructs were used to transform ppi1 plants, and ge-
netic complementation of the ppi1 mutation was assessed in
the T2 generation. The ppi1 mutant is chlorophyll de¢cient as
a result of its chloroplast protein import defect, and so com-
Fig. 3. GTP-hydrolysis assays. A: Wild-type (WT) and mutant (D217N, D219N/E220Q and E208Q) recombinant atToc33vTM proteins were
incubated with [K-32P]GTP for 5, 15, 30 and 60 min. The samples were then separated by TLC and visualised by autoradiography. The lower
band in each case corresponds to unhydrolysed GTP, and the upper band corresponds to GDP. No hydrolysis was observed in a control reac-
tion (C) lacking recombinant protein. B: Radioactivity associated with each band in panel A was quanti¢ed and used to calculate the degree of
GTP hydrolysis at each time-point; each value is expressed as a percentage of the wild-type atToc33vTM 60 min value. C: Similar GTP-hydro-
lysis assays were conducted in the presence of di¡erent concentrations of cold competitor (GTP or XTP, as indicated). Ten-, 100- and 1000-
fold excesses of competitor were employed as shown. Each assay was incubated for 15 min. Once again, no hydrolysis was observed in a con-
trol reaction (C) lacking recombinant protein. D: Radioactivity associated with each GDP band in panel C was quanti¢ed and used to calcu-
late the degree of GTP hydrolysis in each experiment; each value is expressed as a percentage of the value obtained in the absence of competi-
tor using the corresponding protein. All of the presented data are representative of at least two independent experiments.
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plementation of the mutation can easily be assessed by mea-
suring the chlorophyll content of plants [15]. As shown in Fig.
4A, both atToc33D217N and atToc33D219N e⁄ciently comple-
mented the ppi1 chlorophyll de¢ciency, demonstrating that the
putative G4 mutations have no signi¢cant e¡ect on the in vivo
functionality of full-length atToc33 protein. Complementation
of the chlorophyll phenotype correlated with restored expres-
sion of the atToc33 protein at levels comparable to those
present in the wild type (Fig. 4B). Because these in vivo
data are fully consistent with the in vitro data for
atToc33vTMD217N and atToc33vTMD219N described earlier
(Figs. 2 and 3), it seems unlikely that any of the other mutants
would behave di¡erently in vivo.
4. Conclusions
We have analysed the nucleotide-binding and -hydrolysing
properties of atToc33 in detail for the ¢rst time. We found
that atToc33, like psToc34, binds GTP and GDP but not
ATP. Puri¢ed atToc33 was also shown to have intrinsic
GTPase activity, demonstrating that a separate GAP is not
absolutely required. Surprisingly, atToc33 was found to bind
XTP with approximately the same e⁄ciency as GTP and
GDP. Furthermore, mutations within the putative speci¢ci-
ty-determining G4 and G5 motifs of atToc33 did not a¡ect
nucleotide speci¢city, GTPase activity, or (in the case of
D217N and D219N) in vivo functionality. Taken together,
these data demonstrate that atToc33 belongs to a novel class
of GTPases with unusual nucleotide-binding properties, and
support the conclusions drawn from the crystal structure of
psToc34 [13].
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